PolyPid Ltd. SEC Filings

PolyPid Ltd. disclosed that Aurum Ventures M.K.I. Ltd. and Morris Kahn each report beneficial ownership of 5,001,561 ordinary shares, representing 28.1% of the class on a fully-diluted basis that counts 1,918,879 shares issuable upon exercise of currently exercisable warrants. The filing clarifies that the reported totals do not give effect to warrant "blocker" provisions that prevent exercises that would raise beneficial ownership above 9.9% at any given time, so the actual number of shares that can be owned simultaneously is lower than the aggregate reported.

The statement explains that Mr. Kahn is the ultimate sole beneficiary of Aurum and may be deemed to share beneficial ownership of the shares held by Aurum, while disclaiming day-to-day voting or investment control over Aurum-held shares.

PolyPid Ltd. submitted a Form 6-K dated August 13, 2025, furnishing its unaudited interim condensed financial statements and management's discussion and analysis for the six months ended June 30, 2025. The filing includes XBRL-formatted financial information covering interim condensed consolidated balance sheets, statements of operations, shareholders' equity, cash flows and notes, plus an embedded Cover Page Interactive Data File. The report is submitted by the Chief Executive Officer and lists related exhibit numbers for the financial statements, MD&A and XBRL tagging.

PolyPid Ltd. filed a Form S-8 to register 1,200,000 additional ordinary shares for issuance under the Amended and Restated 2012 Share Option Plan, incremental to 2,311,570 shares previously registered. The Registration Statement incorporates by reference the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2024 and specified Form 6-K reports that include recent financial results for the quarters and six-month periods ended June 30, 2025.

The company's amended articles will permit exemption, indemnification and insurance of officers to the fullest extent allowed under Israeli law; PolyPid intends to obtain directors and officers liability insurance and to enter into indemnification and exemption agreements with officers, while noting the SEC view that indemnification against Securities Act liabilities is unenforceable. The filing indicates the company is an emerging growth company and a non-accelerated filer.

Rosalind Advisors, related individuals and a fund report collective beneficial ownership of 5,762,349 common shares of PolyPid Ltd., representing 9.9% of the outstanding common stock based on 15,897,201 shares outstanding per the issuer's disclosure. The reported position consists of 975,462 shares of Common Stock and 4,786,887 shares issuable upon exercise of warrants.

The filings show shared voting and dispositive power over 5,762,349 shares and no sole voting or dispositive power. The warrants include a blocker provision that prevents exercise to the extent it would increase beneficial ownership above 9.99%, and the filing states actual ownership after giving effect to those blockers is less than the amounts reported.

PolyPid Ltd. reports a leadership change and links recent financial disclosures to its U.S. registration statements. The company notes that Jacob Harel’s service as director and chairman ended at the June 25, 2025 shareholder meeting. On August 11, 2025, the board elected existing director Nir Dror as Interim Chairman of the Board, to serve until further notice or another board decision.

The filing also records that on August 13, 2025 PolyPid issued a press release titled “PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results.” Specified sections of that release, including corporate highlights, financial results for the three and six months ended June 30, 2025, balance sheet highlights, forward-looking statements and the attached financial statements, are incorporated by reference into several of PolyPid’s Form F-3 and Form S-8 registration statements.

PolyPid Ltd., an Israel-based biopharmaceutical company, filed a Form 6-K to furnish a press release announcing the appointment of Dr. Nurit Tweezer-Zaks as its Chief Medical Officer. This leadership change relates to oversight of the company’s medical and clinical activities.

The filing also states that the first and third paragraphs of the press release, along with its “Forward-Looking Statements” section, are incorporated by reference into several of PolyPid’s effective registration statements on Forms F-3 and S-8, so that these disclosures become part of those offering documents going forward.

PolyPid held its Annual and Extraordinary General Meeting on June 25, 2025, where shareholders approved all seven proposed resolutions. Key approvals include:

• Re-appointment of Kost Forer Gabbay & Kasierer as independent auditors
• Re-election of eight board members with approved compensation
• New option grants for non-executive directors
• Two separate option grants for CEO Dikla Czaczkes Akselbrad: - Standard option grant - Additional milestone-based option grant
• Renewal of company's compensation policy
• Acceleration of unvested options for departing Board Chairman Jacob Harel

The meeting also included discussion of financial statements for FY2024. The approved changes to compensation and governance structure indicate strategic moves to retain leadership and align management incentives with company performance. The filing was incorporated into multiple Form F-3 and S-8 registration statements.